Salmeterol/fluticasone 50/100 (SFC) dry powder inhaler (DPI) provides improved control and quality of life in patients symptomatic on inhaled corticosteroids (ICS)
T. P. McCarthy, H. M. Edin, K. House, A. K. Vandermeer (Uxbridge, United Kingdom; Research Triangle Park, United States Of America)
Source: Annual Congress 2002 - Asthma - Therapy and management -2
Session: Asthma - Therapy and management -2
Session type: Thematic Poster Session
Number: 408
Disease area: Airway diseases
Abstract Introduction: A randomised, double-blind study demonstrated quality of life and asthma control improvements in patients treated with SFC (Seretide™;) 50/100mcg bd via Accuhaler™; DPI compared with salmeterol (S) 50mcg bd, fluticasone propionate (FP) 100mcg bd & placebo (PL) (SFCA3002). Aim: To examine the patients in this study on ICS at baseline (n=240). Method: Asthma Quality of Life questionnaire (AQLQ) was administered (mean change from baseline >=0.5 is clinically meaningful). Asthma control, probability of remaining in the study, was also evaluated. Results: Patients receiving SFC had significantly greater change from baseline in overall AQLQ score (p[lte]0.025); and superior asthma control compared with all other groups (p[lte]0.007), 2% of patients withdrawing, compared with 11%, 33% & 55% for FP, S & PL.
Mean Change from Baseline in Overall and Asthma Symptom Score SFC FP S PL Overall 0.98 (a,b,c) 0.51 0.26 0.16 Asthma Symptoms 1.04 (a,b,c) 0.62 0.20 0.10 Asthma Control (patients withdrawing from study) 2% (d) 11% 33% 55% a) p[lte]0.003 vs PL, b) p[lte]0.003 vs S, c) p=0.025 vs FP, d) p[lte]0.007 vs FP,S,PL
Discussion: New guidelines recommend adding long-acting β2 agonists as first choice therapy in patients not well controlled on low-moderate doses of ICS. For this group of patients the study shows the significant improvements in quality of life and asthma control achieved with SFC, suggesting this therapy is an effective treatment for control of asthma which can also enhance patients' quality of life.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. P. McCarthy, H. M. Edin, K. House, A. K. Vandermeer (Uxbridge, United Kingdom; Research Triangle Park, United States Of America). Salmeterol/fluticasone 50/100 (SFC) dry powder inhaler (DPI) provides improved control and quality of life in patients symptomatic on inhaled corticosteroids (ICS). Eur Respir J 2002; 20: Suppl. 38, 408
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Patients’ ability to use a novel fluticasone propionate/formoterol breath-triggered inhaler (BTI) vs. budesonide/formoterol dry powder inhaler (DPI) Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018
Differences in patient perceived side effects (PPSE) of inhaled corticosteroids (ICS) between metered dose inhalers (MDI) and dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003
Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 260s Year: 2004
Lower systemic exposure to corticosteroid for fluticasone propionate/salmeterol (500/50mcg bd) compared to budesonide/formoterol (400/12mcg bd) administered via combination dry powder inhalers in subjects with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004
Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Efficacy and safety of the new beclomethasone dipropionate/formoterol combination (HFA MDI) vs. budesonide/formoterol (DPI) in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study. Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020
Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS) Source: Eur Respir J 2004; 24: Suppl. 48, 164s Year: 2004
Single inhaler therapy (SiT) with budesonide/formoterol (BUD/FM) is effective in asthma control Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Budesonide/formoterol (BUD/FORM) single inhaler therapy (SiT) provides greater overall asthma control than traditional fixed dosing (FD) regimens Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004
Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2 agonists (LABA) + inhaled corticosteroids (ICS) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003
Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002
Does health-related quality of life improve with QD and BID dosing of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids? Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003